A Phase 1 interventional study of Sildenafil and Sildenafil in Erectile Dysfunction, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 1 site in Singapore. Open to male participants aged 45 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-01.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing sildenafil in Erectile Dysfunction — 1 open to participants now, 1 under way, 1 of them phase 3. sildenafil · Erectile Dysfunction.
Among the 50 studies testing sildenafil in Erectile Dysfunction, this one is the 47th largest by enrollment, is one of 3 that started in 2010, is one of 6 in phase 1, and was the 34th registered.
702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.
Browse Erectile Dysfunction studies →1 of the 50 studies testing sildenafil in Erectile Dysfunction is open now. Recruiting first, the newest first:
sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 45 Years and older · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 3 · Phase 3 6 · Phase 4 30
First in 2002; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 70 across 551 interventional studies indexed under Erectile Dysfunction.
Median enrollment 108 across the 50 interventional studies. Of the 38 that completed or were terminated, 6 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 50 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
27 studies in Erectile Dysfunction by Viatris Inc.: none open now, none under way, none of them phase 3. Of 27 finished, 5 (19%) have results posted.
Among the 27 studies in Erectile Dysfunction by Viatris Inc., this one is the 24th largest by enrollment of the 24 interventional ones that give a count, is one of 5 that started in 2010, is one of 5 in phase 1, and was the 26th registered.
Viatris Inc.’s Erectile Dysfunction studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 50 studies testing sildenafil in Erectile Dysfunction, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 27 in Erectile Dysfunction:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate if an orally disintegrating tablet of sildenafil will have similar pharmacokinetic properties when given with food and without food.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment A: Sildenafil ODT tablet 50 mg, administered without water under fasted conditions.
Drug: Sildenafil
Treatment B: Sildenafil ODT tablet 50 mg, administered without water under fed conditions.
Drug: Sildenafil
Orally Disintegrating Tablet, 50 mg, Single Dose
Orally Disintegrating Tablet, 50 mg, Single Dose
Maximum Observed Plasma Concentration (Cmax)
Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 14 hrs post-dose
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
Area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration (AUClast).
Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 14 hours (hrs) post-dose
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 14 hrs post-dose
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)]
AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).
Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 14 hrs post-dose
Plasma Decay Half Life (t1/2)
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 14 hrs post-dose
| Milestone | Sildenafil Fasted First, Then Sildenafil Fed | Sildenafil Fed First, Then Sildenafil Fasted |
|---|---|---|
| Started | 6 | 6 |
| Completed | 6 | 6 |
| Not completed | 0 | 0 |
| Milestone | Sildenafil Fasted First, Then Sildenafil Fed | Sildenafil Fed First, Then Sildenafil Fasted |
|---|---|---|
| Started | 6 | 6 |
| Completed | 6 | 6 |
| Not completed | 0 | 0 |
| Milestone | Sildenafil Fasted First, Then Sildenafil Fed | Sildenafil Fed First, Then Sildenafil Fasted |
|---|---|---|
| Started | 6 | 6 |
| Completed | 6 | 6 |
| Not completed | 0 | 0 |
| ng/mL | Sildenafil 50 mg (Fasted) | Sildenafil 50 mg (Fed) |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) | 292.60 ± 93.84 | 121.00 ± 56.92 |
| hrs | Sildenafil 50 mg (Fasted) | Sildenafil 50 mg (Fed) |
|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) | 0.625 (0.250 to 1.500) | 4.000 (0.500 to 6.000) |
AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).
| ng*hr/mL | Sildenafil 50 mg (Fasted) | Sildenafil 50 mg (Fed) |
|---|---|---|
| Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] | 838.60 ± 197.20 | 804.00 ± 284.69 |
Area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration (AUClast).
| ng*hr/mL | Sildenafil 50 mg (Fasted) | Sildenafil 50 mg (Fed) |
|---|---|---|
| Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) | 813.20 ± 186.29 | 712.80 ± 245.58 |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
| hrs | Sildenafil 50 mg (Fasted) | Sildenafil 50 mg (Fed) |
|---|---|---|
| Plasma Decay Half Life (t1/2) | 3.039 ± 0.484 | 2.503 ± 0.359 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sildenafil 50 mg (Fasted) | — | 0/12 (0%) | 3/12 (25%) |
| Sildenafil 50 mg (Fed) | — | 0/12 (0%) | 3/12 (25%) |
| Event | Sildenafil 50 mg (Fasted) | Sildenafil 50 mg (Fed) |
|---|---|---|
| Catheter site haematomaGeneral disorders | 2/12 | 0/12 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 1/12 | 2/12 |
| HeadacheNervous system disorders | 0/12 | 1/12 |
| Dry throatRespiratory, thoracic and mediastinal disorders | 1/12 | 1/12 |
| Dry skinSkin and subcutaneous tissue disorders | 1/12 | 1/12 |
| Age, Continuous(years) | Entire Study Population |
|---|---|
| Mean | 56.6 ± 8.2 |
| Sex: Female, Male(Participants) | Entire Study Population |
|---|---|
| Female | 0 |
| Male | 12 |
The record gives a start of Dec 2010, a primary completion of Jan 2011 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2012, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sildenafil
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →